INGN vs PDEX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
INGN exhibits severe operational distress, highlighted by a critical Piotroski F-Score of 1/9, indicating a significant deterioration in financial health. While the company maintains a strong liquidity position with a Current Ratio of 3.12 and very low debt (D/E 0.09), it is unable to translate this into profitability, as evidenced by negative operating margins and stagnant revenue growth of 2%. There is a stark disconnect between the 'Strong Buy' analyst consensus and the fundamental reality of a 5-year price collapse of 88.6%. The stock currently presents as a classic value trap, trading below book value but lacking the growth catalysts necessary for a reversal.
PDEX exhibits a stable financial profile with a Piotroski F-Score of 6/9 and a strong balance sheet characterized by low leverage and high liquidity. While the current price of $52.60 is above the defensive Graham Number ($31.55), it remains well below the growth-based intrinsic value of $65.81. The company demonstrates exceptional capital efficiency with an ROE of 30.87% and a very healthy current ratio of 4.03. Despite a bearish technical trend indicator, the fundamental growth and profitability metrics suggest significant underlying strength.
Compare Another Pair
Related Comparisons
INGN vs PDEX: Head-to-Head Comparison
This page compares Inogen, Inc. (INGN) and Pro-Dex, Inc. (PDEX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.